Lamotrigine add-on therapy in myoclonic epilepsies

Fragmento

Señor Editor: Lamotrigine (1tg) is a new antiepileptic durg, recently introduced intro Brazil. Current evidence suggests it acts via a blockade of voltage sensitive sodium channels to stalize neuronal membranes, and inhibit exitatory aminoacid release, particulary glutamate. Several controlled trials have demostrated is efficiency in refractory partial seizures, but only limited or the Lennox Gastaut syndrome that has been reported. In an overview of 27 studies involving 572 patients, of the 11 patients with myoclonic seizures only 4 (36%) achieved a greater than 50% reduction in frecuency in the 12 weeks with 1gt. We report it as add-on therapy in two patients with myoclonic epilepsies.

Palabras clave:

2004-08-13   |   1,154 visitas   |   Evalua este artículo 0 valoraciones

Vol. 1 Núm.4. Octubre-Diciembre 1996 Pags. 351 Arch Neurocien Mex 1996; 1(4)